The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?
作者信息
Müller Antonia M S, Kumar Shaji K, Bruno Benedetto
机构信息
Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland.
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
出版信息
Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987.
Abstract
摘要
相似文献
1
The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?骨髓瘤治疗中的继子：异基因移植终究并非那么糟糕？
Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987.
2
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.多发性骨髓瘤中无关供者减低强度预处理后异基因造血干细胞移植的挽救性应用。欧洲血液和骨髓移植慢性恶性疾病工作组浆细胞疾病小组委员会的一项研究。
Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20.
3
Principles and overview of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的原则与概述
Cancer Treat Res. 2009;144:1-21. doi: 10.1007/978-0-387-78580-6_1.
4
Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.非清髓性异基因外周血干细胞移植治疗多发性骨髓瘤
Hong Kong Med J. 2004 Apr;10(2):77-83.
5
Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.减低剂量预处理在多发性骨髓瘤患者异基因造血细胞移植中的作用
Hematol Oncol Stem Cell Ther. 2011;4(1):1-9. doi: 10.5144/1658-3876.2011.1.
6
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.多发性骨髓瘤的异基因造血细胞移植：疾病风险和移植后微小残留病对生存的影响。
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86. doi: 10.1016/j.clml.2016.03.001. Epub 2016 Mar 30.
7
Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.多发性骨髓瘤移植中的争议：序贯自体移植和小型同种异体移植
Bone Marrow Transplant. 2001 Oct;28(8):725-35. doi: 10.1038/sj.bmt.1703254.
8
Pro: allogeneic transplantation in multiple myeloma.优点：多发性骨髓瘤的异基因移植。
Clin Adv Hematol Oncol. 2006 May;4(5):388-91.
9
Isolated orbital relapse of multiple myeloma in a patient with severe chronic GVHD after allogeneic hematopoietic SCT.异基因造血干细胞移植后发生严重慢性移植物抗宿主病的患者出现孤立性眼眶多发性骨髓瘤复发。
Bone Marrow Transplant. 2014 Jul;49(7):988-9. doi: 10.1038/bmt.2014.81. Epub 2014 Apr 28.
10
Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.在多发性骨髓瘤患者中，与自体移植相比，异基因干细胞移植可降低疾病进展。
Bone Marrow Transplant. 2001 Apr;27(8):801-7. doi: 10.1038/sj.bmt.1703006.
本文引用的文献
1
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.自体-异体造血干细胞移植序贯治疗多发性骨髓瘤的长期随访。
Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.
2
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.同种异体移植多发性骨髓瘤患者可能允许在精心选择的患者中实现长期生存，这些患者具有可接受的毒性和保留的生活质量。
Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.
3
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.新诊断多发性骨髓瘤患者自体造血细胞移植的分期系统：修订后的国际分期系统显示组间差异最大。
Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.
4
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.硼替佐米维持治疗的串联自体/异基因造血细胞移植用于高危骨髓瘤。
Blood Adv. 2017 Nov 9;1(24):2247-2256. doi: 10.1182/bloodadvances.2017010686. eCollection 2017 Nov 14.
5
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.自体/异体造血干细胞移植与多发性骨髓瘤的串联自体移植：长期复发后生存的比较。
Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. doi: 10.1016/j.bbmt.2017.10.024. Epub 2017 Oct 24.
6
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.新药对多发性骨髓瘤一线串联自体移植-同种异体移植长期随访的影响。
Biol Blood Marrow Transplant. 2018 Jan;24(1):189-193. doi: 10.1016/j.bbmt.2017.09.017. Epub 2017 Oct 4.
7
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.简明修订的骨髓瘤合并症指数作为801例多发性骨髓瘤患者大样本队列中的有效预后评估工具。
Haematologica. 2017 May;102(5):910-921. doi: 10.3324/haematol.2016.162693. Epub 2017 Feb 2.
8
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.欧洲异基因造血细胞移植治疗多发性骨髓瘤：25 年来的趋势和结果。一项由 EBMT 慢性恶性肿瘤工作组开展的研究。
Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.
9
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤非清髓性同种异体移植后微小残留病的前瞻性分子监测
Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.
10
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.来那度胺维持治疗异基因造血细胞移植后的高危多发性骨髓瘤。
Biol Blood Marrow Transplant. 2014 Aug;20(8):1183-9. doi: 10.1016/j.bbmt.2014.04.014. Epub 2014 Apr 21.
Zotero 插件